Sales Of Johnson & Johnson Esketamine Drug Spravato Rise Nearly 100% Year Over Year
Portfolio Pulse from The Dales Report
Johnson & Johnson (JNJ) reported Q2 2023 results, surpassing analyst forecasts with adjusted earnings per share of $2.80 versus the consensus $2.62. The company also raised its full-year earnings guidance. Notably, sales of its esketamine drug, Spravato, used to treat treatment-resistant depression, grew nearly 100% YoY. Despite initial slow sales due to overpricing claims and inconvenient treatment protocols, Spravato's sales have accelerated over the past quarter.
July 20, 2023 | 7:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson reported strong Q2 2023 results, with a significant increase in sales of its drug, Spravato. This could positively impact the company's stock in the short term.
Johnson & Johnson's strong Q2 2023 results, coupled with the significant increase in sales of its drug, Spravato, indicate a positive financial performance. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100